Cardiovascular disease and lipids. Issues and evidence for the management of dyslipidaemia in primary care.
The commonest manifestations of cardiovascular disease, namely coronary heart disease (CHD) and stroke, represent the two most common causes of death in the world today. Furthermore, cardiovascular diseases have the highest healthcare utilisation costs in most countries. Both primary and secondary p...
Autor principal: | Hobbs, F |
---|---|
Formato: | Journal article |
Idioma: | English |
Publicado em: |
2003
|
Registros relacionados
-
2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk
por: article Editorial
Publicado em: (2020-09-01) -
Effective management of dyslipidaemia among patients with cardiovascular risk: updated recommendations on identification and follow-up.
por: Hobbs, R, et al.
Publicado em: (2005) -
New Perspectives on Atherogenic Dyslipidaemia and Cardiovascular Disease
por: Alberto J Lorenzatti, et al.
Publicado em: (2020-02-01) -
2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS)
por: Mach, F, et al.
Publicado em: (2019) -
Biochemical effects of statins on lipid parameters among newly diagnosed dyslipidaemia subjects in primary care
por: Meor Anuar Shuhaili, Meor Fairuz Rizal, et al.
Publicado em: (2018)